Clarient has launched a new gene expression diagnostic for prostate cancer, the Insight Dx Prostate Profile (Insight). The test, developed in conjunction with Health Discovery Corp., uses expression values from four genes […]
Trod Medical: FDA 510(k) Clearance for Encage
Trod Medical has received FDA 510(k) clearance for Encage, a minimally invasive technology for soft tissue ablation. The surgical system allows for precise percutaneous ablation of target tissue with well-defined margins, helping […]
Endocare and Galil Medical to Merge
Only months after Healthtronics withdrew its offer to acquire Endocare for $2.28 per share, Endocare and privately held Galil Medical have agreed to merge. The combined company will be focused on the […]
Clarient: Q3 Revenues up 59%; Raises Guidance
Third quarter revenues at Clarient increased 59% to $19.0 million from the $11.9 million reported in Q3 2007. This marks the company’s 17th consecutive quarter of sequential revenue growth. Higher testing volume, […]
Medtech Insight: In3 East
Meet the most important people in medical technology at In3 East, the largest East Coast strategic partnership and investment meeting for senior-level medical technology executives. Hundreds of venture capital companies and medical […]
Definiens Collaboration to Add Technological Muscle to Clarient’s Offerings in Personalized Medicine
In a move that could accelerate the growth of the Clarient’s biomarker business, the company announced Friday that, with Definiens, it will develop and commercialize tools to help evaluate quantitative biomarkers that […]
Clarient Q2 Revenues Up 71%
Not wanting to break a winning streak, Clarient delivered its 16th consecutive quarter of quarterly revenue growth. The company posted revenues of $16.9 million in its most recent quarter, a 71% increase […]
Cancer Researchers See the Light: Caliper Life Sciences Intruduces Bioware Ultra
Five cancer cells were injected subcutaneously into the dorsal region near the thigh of mouse. Tumor growth is monitored weekly by an IVIS Spectrum. The tumor was visible 28 days post implantation; […]
